BRIEF REPORT

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance

Stephanie A. Meyers-Pantele1,2†, Maria Luisa Mittal1,3†, Sonia Jain4, Shelly Sun4, Indhu Rammohan5, Nadia Fairbairn6,7, M-J Milloy6,7, Kora DeBeck6,8, Kanna Hayashi6,9 and Dan Werb1,5*

Abstract

Background: Evidence suggests people who inject drugs (PWID) prescribed opioid agonist treatment (OAT) are less likely to provide injection drug use (IDU) initiation assistance. We investigated the association between OAT engagement and providing IDU initiation assistance across poly-drug use practices in Vancouver, Canada.

Methods: Preventing Injecting by Modifying Existing Responses (PRIMER) is a prospective study seeking to identify structural interventions that reduce IDU initiation. We employed data from linked cohorts of PWID in Vancouver and extended the findings of a latent profile analysis (LPA). Multivariable logistic regression models were performed separately for the six poly-drug use LPA classes. The outcome was recently assisting others in IDU initiation; the independent variable was recent OAT engagement.

Results: Among participants (n = 1218), 85 (7.0%) reported recently providing injection initiation assistance. When adjusting for age and sex, OAT engagement among those who reported a combination of high-frequency heroin and methamphetamine IDU and low-to-moderate-frequency prescription opioid IDU and methamphetamine non-injection drug use (NIDU) was associated with lower odds of IDU initiation assistance provision (Adjusted Odds Ratio [AOR]: 0.18, 95% CI: 0.05–0.63, \( P = 0.008 \)). Significant associations were not detected among other LPA classes.

Conclusions: Our findings extend evidence suggesting that OAT may provide a population-level protective effect on the incidence of IDU initiation and suggest that this effect may be specific among PWID who engage in high-frequency methamphetamine and opioid use. Future research should seek to longitudinally investigate potential causal pathways explaining the association between OAT and initiation assistance provision among PWID to develop tailored intervention efforts.

Keywords: Opioid agonist treatment, Overdose prevention, HIV prevention, HCV prevention, Persons who inject drugs, Methadone, Suboxone, Treatment as prevention

Introduction

People who inject drugs (PWID) play a key role in injection drug use (IDU) initiation processes, with 68–88% of IDU initiates reporting they received education, guidance, or were directly injected by more experienced PWID during their initiation event.

†Stephanie A. Meyers-Pantele and Maria Luisa Mittal contributed equally to this work.
*Correspondence: dwerb@health.ucsd.edu
5 Centre on Drug Policy Evaluation, St. Michael’s Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
PWID are also impacted by a variety of injection-related harms, including overdose, HIV, hepatitis C, and bacterial infections [4, 5]; they are also at greatest risk for these harms within the first 5 years of initiating IDU [6, 7]. Given the documented vulnerability of PWID that have recently transitioned into IDU, it is critical that research and harm reduction efforts be directed towards preventing transitions into this mode of substance use, particularly in settings like Vancouver, Canada that are disproportionately impacted by the North American overdose crisis [8–10].

Preliminary evidence suggests that PWID on opioid agonist treatment (OAT) are less likely to report initiating others into IDU [11, 12]. Specifically, PWID from both San Diego and Vancouver that reported a history of OAT had significantly decreased odds (Vancouver: Adjusted Odds Ratio [AOR] = 0.52; 95% Confidence Interval [CI] = 0.31–0.87) of providing IDU initiation assistance [11, 12]. For people who inject opioids, OAT mitigates withdrawal symptoms and effectively reduces the frequency of injecting unregulated opioids [13, 14]; we hypothesize that OAT may also reduce the frequency with which PWID expose injection-naïve individuals to IDU, thereby reducing the potential for PWID to encounter requests for injection initiation assistance. Further, it is estimated that an expansion of OAT coverage to 40%, 50%, or 60% for PWID could reduce injection initiation events by 11.5%, 17.3%, and 22.8% per annum, could potentially reduce PWID population size, and the expansion of opioid- and injection-related epidemics [15, 16]; though data on the potential impact of OAT among polydrug-using subpopulations is lacking.

Recent evidence suggests that the prevalence of methamphetamine and other poly-drug use is increasing among PWID who use opioids in North America [17–19]. This is concerning given that those who inject methamphetamine in conjunction with opioids are at greater risk for injection-related harms, including overdose, compared to PWID who inject only opioids [20]. Furthermore, methamphetamine use has been associated with IDU initiation in Vancouver and Tijuana, Mexico [21, 22], and with providing injection initiation assistance to others among PWID in Tijuana [22]. This suggests that efforts to prevent injection initiation, such as the provision of OAT to PWID who provide injection initiation assistance, should focus on specific subpopulations of PWID at highest risk. As such, the current study sought to further investigate whether previously-identified protective associations between OAT engagement and injection initiation assistance provision [12] were found across PWID with differing poly-drug use practices in Vancouver, Canada.

**Methods**

**Study design**

The PREventing Injecting by Modifying Existing Responses (PRIMER) study seeks to assess the impact of socio-structural factors on the risk that PWID provide injection initiation assistance [3]. The PRIMER study protocol and rationale have been previously described [3]. For the present analysis, data were drawn from three linked open prospective cohort studies of people who use drugs (PWUD) in Vancouver, Canada: The At-Risk Youth Study (ARYS; street-involved youth aged 14–26 who use drugs), the AIDS Care Cohort to evaluate Exposure to Survival Services study (ACCESS; HIV-seropositive adult [≥18 years of age] PWUD), and the Vancouver Injection Drug Users Study (VIDUS; HIV-seronegative adult PWID). To be eligible, participants had to report unregulated use of (i.e., illegal/street-based) drugs other than cannabis ≤30 days prior to baseline. The PRIMER baseline is defined as the visit when specific survey items soliciting reports of assisting others in their first injection were introduced into the cohort questionnaires (December, 2014–May, 2017). The current study is cross-sectional and was restricted to participants who reported past six-month IDU at PRIMER baseline. The inclusion criterion of recent IDU was selected given that the provision of IDU initiation assistance is a relatively rare event [23, 24], and that focusing on the population most likely to provide this assistance would allow for the most accurate description of the phenomena of interest [1, 3]. This study was approved by Institutional Review Boards at UC San Diego and the University of British Columbia-Providence Health Care. All participants provided written informed consent.

**Measures**

Participants completed an interviewer-administered questionnaire assessing sociodemographics, drug use behaviors, health services enrollment, and other domains. The primary outcome, recently assisting others in their first injection, was assessed via the following survey item: “In the past six months, have you helped someone inject who had never injected before?” The independent variable, recent OAT engagement, was defined via endorsement of the statement: “In the past six months have you been in (methadone/metha-dose program or Suboxone) treatment?” The covariates of age and sex (i.e., male/female) were selected based on previous studies of IDU initiation assistance [22–24], and all variables of interest were captured at participants’ PRIMER baseline visit. Analyses were stratified based on drug use practices identified within a previously conducted latent profile analysis (LPA) ([25]; Rammohan I, Jain S, Sun X, Marks C, Milloy...
M-J, Hayashi K, et al: Identifying latent polydrug use patterns and assessing their association with the provision of injection initiation assistance in three north American settings: a latent profile analysis, In Preparation). The LPA methods have previously described in full; briefly, six classes of poly-drug use were identified based on participants’ recent IDU and non-injection (NIDU) drug type (i.e., methamphetamine, heroin, cocaine, and prescription opioids [PO]) and frequency of use (i.e., low, moderate, and high) ([25]; Rammohan I, Jain S, Sun X, Marks C, Milloy M-J, Hayashi K, et al: Identifying latent polydrug use patterns and assessing their association with the provision of injection initiation assistance in three north American settings: a latent profile analysis, In Preparation).

Statistical analyses
Cross-sectional bivariate associations between OAT engagement and providing IDU initiation assistance were assessed among each LPA class using cross-tabulation and Fisher’s exact tests. Multivariable logistic regression models were performed for each LPA class separately to study the independent association of reporting OAT use on the provision of injection initiation assistance while controlling for age and sex. Analyses were performed using R software (version 3.5.1). Two-sided P-values < 0.05 were considered statistically significant.

Results
Among 1218 participants, 162 participants (13.3%) were in Class 1, defined by past six-month high-frequency methamphetamine IDU and low-to-moderate NIDU (Table 1). Additionally, 128 (10.5%) participants were in Class 2, defined by moderate-to-high-frequency heroin IDU, high-frequency heroin NIDU, and moderate-to-high-frequency methamphetamine IDU and NIDU. Nearly a quarter (n = 295; 24.2%) were in Class 3, defined by low-frequency heroin, methamphetamine,

Table 1  Association between OAT and Provision of Injecting Initiation Assistance among PWID subgroups in Vancouver, Canada (n = 1218)

| Class Description                                                                 | OAT=No   | OAT=Yes  | Total  | P-value* |
|----------------------------------------------------------------------------------|----------|----------|--------|----------|
| 1. High Frequency Methamphetamine IDU; Low-to-Moderate NIDU                      | 98 (87.5%) | 14 (12.5%) | 112 (69.1%) | 0.152 |
| Total                                                                            | 146 (90.1%) | 16 (9.9%)  | 162    |          |
| 2. Moderate-to-High Frequency Heroin IDU; High Frequency Heroin NIDU, and Moderate-to-High Frequency Methamphetamine IDU and NIDU | 55 (88.7%) | 7 (11.3%) | 62 (48.4%) | 0.792 |
| Total                                                                            | 112 (87.5%) | 16 (12.5%) | 128    |          |
| 3. Low Frequency Use of All Drugs                                               | 133 (97.8%) | 3 (2.2%) | 136 (46.1%) | > 0.999 |
| Total                                                                            | 289 (98.0%) | 6 (2.0%) | 295    |          |
| 4. High Frequency Heroin IDU and Methamphetamine IDU, and Low-to-Moderate Frequency PO IDU and Methamphetamine NIDU | 86 (81.1%) | 20 (18.9%) | 106 (52.7%) | < 0.001 |
| Total                                                                            | 178 (88.6%) | 6 (2.0%) | 201    |          |
| 5. High Frequency Heroin IDU                                                     | 96 (91.4%) | 9 (8.6%) | 105 (27.7%)  | 0.121 |
| Total                                                                            | 263 (94.3%) | 16 (5.7%) | 379    |          |
| 6. High Frequency Cocaine IDU and Low-to-Moderate Heroin IDU                    | 61 (95.3%) | 3 (4.7%) | 64 (41.8%)  | > 0.999 |
| Total                                                                            | 145 (94.8%) | 8 (5.2%) | 153    |          |

* Fisher’s exact test

The class refers to activities during the previous six months

| IDU | Injection Drug Use, NIDU | Non-Injection Drug Use, OAT | Opioid Agonist Treatment |
cocaine, and PO IDU and NIDU. Seventeen percent of participants ($n=201; 16.5\%$) were in Class 4, defined by high-frequency heroin and methamphetamine IDU, low-to-moderate-frequency PO IDU, and methamphetamine NIDU. Further, 279 (22.9\%) were in Class 5, defined by high-frequency heroin IDU. Lastly, 153 (12.6\%) participants were in Class 6, defined by high-frequency cocaine IDU and low-moderate heroin IDU. The proportion reporting recent OAT engagement was 51.9\% in the overall sample and was 30.9\% (Class 1), 51.6\% (Class 2), 53.9\% (Class 3), 47.3\% (Class 4), 62.4\% (Class 5), and 58.2\% (Class 6) among each class, respectively. The proportion reporting providing recent injecting initiation assistance in the overall sample was (7.0\%) and 9.9\% (Class 1), 12.5\% (Class 2), 2.0\% (Class 3), 11.4\% (Class 4), 5.7\% (Class 5), and 5.2\% (Class 6) in each group, respectively.

We conducted six separate multivariable regression models for each LPA-identified poly-drug use class with age and sex included as covariates (Table 2). Among a subset of participants characterized by high-frequency heroin and methamphetamine IDU, low-to-moderate-frequency PO IDU, and methamphetamine NIDU (Class 4), participants who reported recent OAT engagement had significantly lower odds of reporting recent injection initiation assistance ($AOR: 0.18, 95\% CI: 0.05–0.63, P=0.008$). The association between OAT engagement and injection initiation assistance was not significant among other LPA classes.

### Discussion

We found a protective association against providing injection initiation assistance among PWID who were recently enrolled in OAT and who had recently engaged in high-frequency heroin and methamphetamine IDU, low-to-moderate-frequency PO IDU, and methamphetamine NIDU, but not among those reporting other poly-drug use patterns. This expands our understanding of the benefits of OAT with respect to the risk of providing injection initiation assistance [11–14]. While methamphetamine IDU has been associated with providing initiation assistance among PWID [22], our findings imply that the potential protective effect of OAT on initiation assistance provision may be heightened among PWID who inject methamphetamines in conjunction with heroin and PO.

We did not find significant associations between OAT and providing initiation assistance among those reporting methamphetamine and heroin IDU, without PO, or among those reporting high-frequency cocaine IDU and low-to-moderate heroin IDU. These findings could potentially reflect limited statistical power to detect associations within some classes given the small size of some subgroups. To that end, they highlight the need for future research to more fully investigate OAT engagement among PWID with varying poly-drug use patterns. Nevertheless, our findings extend previous research demonstrating that people enrolled in OAT and who use cocaine are more likely to report continued cocaine and heroin use when accessing these services compared to those who use other substances [26, 27]. The current findings potentially indicate that alternative therapeutic approaches (e.g., buprenorphine), OAT dosing strategies, or tailored OAT engagement supports are needed to meet the needs of individuals who engage in complex poly-drug use [28].

Previous research indicates that PWID who report injecting in the presence of injection-naive individuals

### Table 2

Multivariable logistic regression models assessing the association between assisting others in their first injection and OAT engagement in Vancouver, Canada

| Variable | AOR (95% CI) | P-value  |
|----------|-------------|----------|
| 1. High Frequency Methamphetamine IDU; Low to Moderate NIDU ($n=162$) | | |
| OAT engagement$^a$ | 0.34 (0.07–1.60) | 0.173 |
| Age | 0.97 (0.92–1.02) | 0.224 |
| Male sex | 4.64 (0.99–21.65) | 0.051 |
| 2. Moderate-to-High Frequency Heroin IDU; High Frequency Heroin IDU; Moderate-to-High Frequency Methamphetamine IDU and NIDU ($n=127$) | | |
| OAT engagement$^a$ | 2.04 (0.64–6.49) | 0.230 |
| Age | 0.94 (0.87–1.01) | 0.094 |
| Male sex | 0.64 (0.21–1.93) | 0.427 |
| 3. Low Frequency Use of All Drugs ($n=295$) | | |
| OAT engagement$^a$ | 1.71 (0.29–10.26) | 0.557 |
| Age | 0.91 (0.84–0.98) | 0.014 |
| Male sex | 1.25 (0.21–7.40) | 0.808 |
| 4. High Frequency Heroin IDU and Methamphetamine IDU; Low-to-Moderate Frequency PO IDU and Methamphetamine NIDU ($n=199$) | | |
| OAT engagement$^a$ | 0.18 (0.05–0.63) | 0.008 |
| Age | 0.96 (0.91–1.01) | 0.105 |
| Male sex | 1.89 (0.68–5.23) | 0.222 |
| 5. High Frequency Heroin IDU ($n=279$) | | |
| OAT engagement$^a$ | 0.46 (0.16–1.32) | 0.148 |
| Age | 0.93 (0.89–0.98) | 0.003 |
| Male sex | 1.37 (0.47–3.95) | 0.565 |
| 6. High Frequency Cocaine IDU; Low-to-Moderate Heroin IDU ($n=153$) | | |
| OAT engagement$^a$ | 1.02 (0.22–4.79) | 0.978 |
| Age | 0.90 (0.83–0.97) | 0.005 |
| Male sex | 0.42 (0.08–2.16) | 0.299 |

$^a$ The variable refers to activities during the previous six months

AOR Adjusted Odds Ratio, 95% CI 95% Confidence Interval, IDU Injection Drug Use, NIDU Non-Injection Drug Use, OAT Opioid Agonist Treatment
are more likely to be asked to provide initiation assistance [1], and that acquiescing to requests often occurs within withdrawal and economic need contexts [29]. Though we found no association between OAT engagement and providing initiation assistance among those who solely engaged in high-frequency heroin IDU, past research has also found higher proportions of PWID who perceive their OAT dosage to be “too low” reported assisting others compared to those who perceived an “adequate” or “high” dosage [12]. As such, if OAT alleviates experiences of withdrawal, it could buffer against requests for initiation for experienced PWID [30]. This further suggests that PWID who report methamphetamine, heroin, and PO IDU could benefit from OAT provision and supports to reduce PWID engagement in IDU initiation events. However, recent evidence from Vancouver demonstrates that methamphetamine use is associated with OAT discontinuation [31], which complicates efforts to retain those at highest risk of providing initiation assistance. The current study indicates, however, that achieving retention among the subpopulation of PWID reporting methamphetamine and opioid (e.g., heroin and PO) IDU may yield a secondary community-level preventive benefit by potentially reducing injection initiation assistance incidence.

Limitations
This study has limitations typical of observational cross-sectional research. Non-probability sampling was used for participant recruitment due to the mobile nature of the population and the corresponding difficulty of developing a sampling frame. Consequently, we cannot assume generalizability for the population of PWID in this study setting. Secondly, we relied on self-report, and underreporting of experiences of initiating others into injecting is likely given it is highly stigmatized, particularly within the context of an overdose crisis [32]; however, research suggests that PWID accurately self-report OAT engagement [33] and substance use-related behaviors [34], indicating these measures are valid. Additionally, to protect against potential response bias, participants were notified of the confidential nature of the study. Third, given the cross-sectional nature of the data collected and the fact that we did not construct causal inference models, we cannot determine causality among OAT engagement and reductions in providing IDU initiation assistance. Further, given that we conducted separate multivariable analyses for each LPA class, we cannot directly compare findings between classes. Finally, we were limited in the number of covariates we could include in our multivariable models due to small subsample sizes and because our outcome was a rare event. Small subsample sizes could have also increased the likelihood of committing Type II error and potentially limited the statistical significance of the study findings [35]. Nevertheless, the findings of this study are in-line with similar studies that found associations between substance use, OAT engagement, and injection initiation events [11, 22].

Conclusion
These findings suggest that, beyond OAT’s effectiveness in managing opioid use disorder, it may also have a secondary protective effect on the expansion of IDU among high-risk populations, including those engaging in high frequency polysubstance use (i.e., methamphetamine, heroin, and PO in combination). This further indicates the need to assess whether OAT service expansion among PWID populations who concurrently inject multiple substances, including methamphetamine and opioids, may reduce the incidence of IDU initiation. These efforts could have the potential to limit transitions into drug injecting, and consequently reduce injection-related harms, including overdose and blood-borne disease transmission.

Acknowledgements
The authors thank the study participants for their contribution to the research, as well as current and past VIDUS/ARYS/ACCESS/PRIMER researchers and staff. Dr. Mittal is supported by the Fogarty International Center of the National Institutes of Health (NIH) Award Numbers D43TW008633 and R25TW009343, UC San Diego Center for AIDS Research (CFAR) NIAID P30AI36214, National Institute on Drug Abuse (NIDA) grants T32DA023356 and 3R01DA040648-02S1. Dr. Meyers-Pantele is supported by NIDA grants R01 DA039950 and T32 DA023356. The PRIMER study is supported by a US NIDA Avenir Award (DP2-DA040256-01) and the Canadian Institutes of Health Research (2020-10-15-452538). Dr. Werb is supported by the St. Michael’s Hospital Foundation. The VIDUS and ARYS Studies are supported by NIDA grant U01DA038886. The ACCESS Study is supported by NIDA grant U01DA21525. Dr. Milloy is supported by NIDA (U01-DA0251525). Dr. Milloy is the Canopy Growth professor of cannabis science at UBC, a position created through unstructured gifts to UBC from Canopy Growth, a licensed producer of cannabis, and the Government of British Columbia’s Ministry of Mental Health and Addiction. Dr. Hayashi holds the St. Paul’s Hospital Chair in Substance Use Research and is supported in part by NIDA (U01-DA038886), a MSFHR Scholar Award, and the St. Paul’s Foundation.

Authors’ contributions
SMP: Conceptualization, Validation, Writing – Original Draft Preparation. MLM: Conceptualization, Methodology, Writing – Original Draft Preparation. SJ: Data Curation, Formal Analysis, and Validation. SS: Data Curation, Formal Analysis, and Validation. IR: Validation and Writing – Reviewing and Editing. Nadia Fairbairn: Writing – Reviewing and Editing. MIM: Methodology, Investigation, Writing – Reviewing and Editing. KD: Methodology, Investigation, Writing – Reviewing and Editing. KH: Supervision, Methodology, Investigation, Writing – Reviewing and Editing. DW: Conceptualization, Methodology, Supervision, Resources, Writing – Reviewing and Editing, Funding Acquisition. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding
Dr. Mittal is supported by the Fogarty International Center of the National Institutes of Health (NIH) Award Numbers D43TW008633 and R25TW009343, UC San Diego Center for AIDS Research (CFAR) NIAID P30AI36214, National Institute on Drug Abuse (NIDA) grants T32DA023356 and 3R01DA040648-02S1. Dr. Meyers-Pantele is supported by NIDA grants R01 DA039950 and T32 DA023356. The PRIMER study is supported by a US NIDA Avenir Award (DP2-DA040256-01) and the Canadian Institutes of Health Research
References
1. Bluthenthal RN, Wengler L, Chu D, Lorvick J, Thing JP, Kral AH, et al. Factors associated with being asked to initiate someone into injection drug use. Drug Alcohol Depend. 2015;149:252–8.
2. Werb D, Buxton J, Shoveller J, Richardson C, Rowell G, Wood E. Interventions to prevent the initiation of injection drug use: a systematic review. Drug Alcohol Depend. 2013;133(2):669–76. https://doi.org/10.1016/j.drugalcdep.2013.08.017.
3. Werb D, Garfein R, Kerr T, Davidson P, Roux P, Jauffret-Roustide M, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduct J. 2016;13(1):25.
4. Mathers BM, Degenhardt L, Bucelló C, Lemo J, Wiessing L, Hickman M. Injection drug use patterns and the provision of injection initiation assistance in three north American settings. Harm Reduct J. 2018;15(1):59.
5. Liebling EJ, Green TC, Hadland SE, Marshall BD. Injection drug use and overdose among young adults who use prescription opioids non-medically. Addict Behav. 2018;76:20–6 Available from: https://www.sciencedirect.com/science/article/pii/S0306460317302691.
6. Garfein RS, Doherty MC, Monterrosa ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr. 1998;18:511–9 Available from: http://journals.lww.com/ajids/Fulltext/1998/02001/Prevalence_and_Incidence_of_Hepatitis_C_Virus.4.aspx.
7. Goldsam LA, Harocopos A, Kobrak P, Jost JT, Clatts MC. Circumstances, pedagogy and rationales for injection initiation among new drug injectors. J Commun Health. 2011;36(3):258–67.
8. Government of Canada. National report: apparent opioid-related deaths in Canada. 2018. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-march-2018.html.
9. Canadian Institute for Health Information. Opioid crisis having “significant” impact on Canada’s health care system. 2018.
10. Centers for Disease Control and Prevention (CDC). Drug overdose deaths in the U.S. top 100,000 annually. National Center for health statistics. 2021. Available from: https://www.cdc.gov/nchs/pressroom/pubs/releas/2021/20211111.htm.
11. Mittal ML, Vashishtha D, Sun S, Jain S, Cuebas-Mota J, Garfein R, et al. History of medication-assisted treatment and its association with initiating others into injection drug use in San Diego, CA. Subst Abus Treat Prev Policy. 2017;12(1):1–5.
12. Mittal ML, Jain S, Sun S, DeBeck K, Milloy MJ, Hayashi K, et al. Opioid agonist treatment and the process of injection drug use initiation. Drug Alcohol Depend. 2019;197:354–60 Available from: https://www.sciencedirect.com/science/article/abs/pii/S0376871619300249. [cited 2019 Jul 5].
13. Karki P, Shrestha R, Huedo-Medina TB, Cepenhamer M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2:1–11.
14. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies - tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–6.
15. Morozova O, Crawford F, Cohen T, Patiel DA, Altic F. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction. 2019;115(1):1–22.
16. Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, et al. Opioid agonist treatment scale-up and the initiation of injection drug use: a dynamic modeling analysis. PLoS Med. 2019;16(11):e1002973. https://doi.org/10.1371/journal.pmed.1002973.
17. Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244–50.
18. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20.
19. Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of “twin epidemics”: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:1–4.
20. Al-Tayyib A, Koester S, Langegger S, Raville L. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52(8):1051–8.
21. Werb D, Kerr T, Buxton J, Shoveller J, Richardson C, Montaner J, et al. Crystal methamphetamine and initiation of injection drug use among street-involved youth in a Canadian setting. CMAJ. 2013;185(18):1569–75. https://doi.org/10.1016/j.drgalcdep.2013.03.011.
22. Ben Hamida A, Rafful C, Jain S, Sun S, Gonzalez-Zuniga P, Rangel G, et al. Non-injection drug use and injection initiation assistance among people who inject drugs in Tijuana, Mexico. J Urban Heal. 2018;95(1):83–90.
23. Meyers SA, Scheim A, Jain S, Sun X, Milloy MJ, DeBeck K, et al. Gender differences in the provision of injection initiation assistance: a comparison of three north American settings. Harm Reduct J. 2018;15(1):59.
24. Meyers-Pantele SA, Jain S, Sun X, Marks C, DeBeck K, Hayashi K, et al. Gender and the first-time provision of injection initiation assistance among people who inject drugs across two distinct North American contexts: Tijuana, Mexico and Vancouver, Canada. Drug Alcohol Rev. 2021;n/a(n/a).
25. Rammohan I, Jain S, Sun S, Marks C, Milloy MJ, Hayashi K, et al. Polydrug use patterns and the provision of injection initiation assistance in Vancouver, Canada, and Tijuana, Mexico: a latent profile analysis. In: NIDA International, 2020.
26. Roux P, Lions C, Vilotitch A, Michel L, Mora M, Maradan G, et al. Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study). Harm Reduct J. 2016;13(12):1–10.
27. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health. 1995;85(1):83–8.
28. Farnum SO, Makarenko I, Madden L, Nazhnaya A, Marcus R, Prokhorova T, et al. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction. 2021;116(1):83–93.
29. Guise A, Melo J, Mittal ML, Rafful C, Cuevas-Mota J, Davidson P, et al. A fragmented code: the moral and structural context for providing assistance with injection drug use initiation in San Diego, USA. Int J Drug Policy. 2018;55(June 2017):51–60.
30. Guise A, Horyniak D, Melo J, McNeil R, Werb D. The experience of initiating injection drug use and its social context: a qualitative systematic review and thematic synthesis. Addiction. 2017;112(12):2098–111.
31. Mackay L, Bach P, Milloy M-J, Cui Z, Kerr T, Hayashi K. The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs. Drug Alcohol Depend. 2021;225:108844 Available from: https://www.sciencedirect.com/science/article/pii/S0376871621003392.
32. Olding M, Werb D, Guise A, Small W, Mcneil R. Navigating social norms of injection initiation assistance during an overdose crisis: a qualitative study of the perspectives of people who inject drugs (PWID) in Vancouver, Canada. Int J Drug Policy. 2019;69:24–33.
33. Bouck Z, Tricco A, Rosella L, Ling V, Gomes T, Tadrous M, et al. Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. Epidemiology. 2021;33(2):287–94.
34. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63.
35. Tabachnik BG, Fidell LS. Using multivariate statistics. 6th ed. Northridge, California: Pearson; 2013.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.